QT-019C
/ Xiniao Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 03, 2026
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital, China
New P1 trial • ANCA Vasculitis • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Myositis • Rheumatology • Scleroderma • Systemic Lupus Erythematosus • Systemic Sclerosis • Thrombocytopenia • Vasculitis
1 to 1
Of
1
Go to page
1